The rare, fatal lympho-proliferative condition: Multicentric Castleman's Disease — MCD — could soon be treatable following findings announced at the American Society of Hematology annual meeting in New Orleans. Dr. Raymond S Wong MD, PhD — who is a hematology consultant at the Prince of Wales Hospital and The Chinese University of Hong Kong — presented data from a multi-national randomized placebo controlled phase 2 study with 79 patients showing remissions in patients treated with the anti-interleukin-6 monoclonal antibody siltuximab.
Dr. Wong and Dr. Joseph Mikhael MD, Consultant Hematologist at the Mayo Clinic in Scottsdale Arizona (speaking on behalf of the American Society or Hematology) discuss the findings and the clinical potential these hold out.
Wong RS et al. “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castleman's Disease.” — Oral presentation presented at: 55th American Society of Hematology (ASH) Annual Meeting; Dec. 7-11, 2013; New Orleans, LA.